Wonga collapses into administration
Payday lender Wonga has collapsed into administration.
Following the collapse on Thursday, the 200,000 customers still owning a combined total of £400 million were told to keep making payments.
The Financial Conduct Authority said: “Customers should continue to make any outstanding payments in the normal way. All existing agreements remain in place and will not be affected by the proposed administration.”
Wonga has long been a controversial short-term lender, where interest rates rocketed to as high as 5,853 percent before the government capped them at 1,500 percent.
A spokesman for the Financial Ombudsman Service said: “We are aware of the recently announced news about Wonga’s administration. Due to the nature of the business, there is no protection offered to consumers under the Financial Services Compensation Scheme (FSCS) in this instance.”
“Once the administrators have been appointed, we’ll speak to them urgently to clarify the impact on the cases we have with us and whether we’ll be able to work any new cases brought to us after today. We do not yet know what, if any, funds will be available to settle complaints.”
The collapse of Wonga will put almost 500 jobs at risk.
The group raised an emergency £10 million from shareholders in August but the surge of compensation claims swung the group into heavy losses.
Jonathan Reynolds, the shadow economic secretary, did not express sadness at the company’s administration.
“Its business model was exploitative and immoral. Wonga had become a testament to so much that is wrong with our economy – too many people stuck in insecure employment reliant on short-term debt just to keep their heads above water.”
“We need urgent action from the government to change this broken model and review the way lending is regulated.”
Martin Lewis, the founder of MoneySavingExpert, said: “Normally when firms go bust, the fear is diminished competition. Not here. Wonga’s payday loans were the crack cocaine of debt – unneeded, unwanted, unhelpful, destructive and addictive. Its behaviour was immoral, from using pretend lawyers to threaten the vulnerable, to pumping its ads out on children’s TV.”
Sativa Investments appoints new CFO following the UK’s legalisation of medicinal cannabis
Sativa Investments PLC (LON: SATI) has appointed Joseph Colliver FCA as Chief Financial Officer and a Director.
Colliver has held past directorships and partnerships in Headlight Vision Limited and Henley Centre Headlight Vision Ltd. With his new appointment at Sativa Investments, he has been granted 3,350,000 share options at 1.5p.
Sativa Investments is the UK’s first medicinal cannabis investment vehicle. The company focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis.
Sativa Investments also aims to drive the research and development of cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.
Currently, Sativa Investments has four investments. Canada-based Veritas Pharma Inc., Toronto-based Rapid Dose Therapeutics Inc., UK-based CBD products provider George Botanicals and PhytoVista.
Commenting on the company’s new CFO appointment, founder and CEO of Satvia Investments, Geremy Thomas, has said: “With four investments to date and a pipeline of potential investments at varying stages of review, the Company needs an experienced, strategically-thinking full-time finance head.”
Medicinal cannabis was legalised in the UK earlier this year. After being advised by the Advisory Council on the Misuse of Drugs, doctors will be permitted to prescribe medicinal cannabis for its therapeutic benefits within months. Products will only be prescribed provided they meet safety standards.
Recent studies have shown that cannabis can be useful for the treatment of chronic pain, spasticity, nausea and vomiting in chemotherapy and drug-resistant epilepsy, just to name a few conditions.
Forbes have recently recorded that spending on legal cannabis worldwide is expected to hit $57 billion by 2027. North America will be home to the largest group of cannabis buyers, going from $9.2 billion in 2017 to $47.3 billion a decade later. However, the largest growth is predicted to be in the rest-of-world markets. Figures in this area are predicted to rise from $52 million spent in 2017 to $2.5 billion.
Glint is set for success following successful Crowdcube campaign
Fintech firm Glint have followed in the footsteps of predecessors such as Revolut and capitalised on early success, by utilising the publicly accessible crowdfunding platform, Crowdcube.
Glint was founded in 2015 but only began fulfilling its potential this year, with recent partnerships with two US financial groups expanding their potential user base by over 40 million.
The British company began their crowdfunding campaign with the aim of raising £1.25 million, and have since gone on to raise £2.045 million, 163% of their original target, with less than a day remaining until their public offering closes.
The company are attempting to revolutionise the volatile currency and payment market by looking to the past.
“Inflation is rising, cost of living increasing and return on cash savings decreasing – so what are our choices? Gold. Gold has maintained its purchasing power for millennia whilst the value of paper money continuously erodes. Gold offers protection of purchasing power in a way that cash doesn’t. The challenge – we live in a digital world.”
The firm’s aim is to reestablish gold as a viable currency by using a vault in Switzerland to store users’ physical gold resources, and then convert these into a currency of the users’ choice, which can be accessed via the recently launched Glint app or Mastercard. In exchange for the service, Glint are charging a 0.5% conversion rate.
Glint is just one of many new and innovative firms basing their venture capital campaigns on Crowdcube, with many now opting for this platform over corporate investment opportunities. Crowdcube sets itself apart in the way that it is open to large capital investors but also inexperienced members of the general public, which is a mutually beneficial arrangement for all parties. The general public have access to the most exciting investment opportunities, and businesses have the opportunity to market their services to the broadest possible scope of potential investors.
GSK secure approval for Nucala asthma treatment
GlaxoSmithKline Plc (LON:GSK) have secured approval for a licence extension of their Nucala treatment for children with severe asthma.
The treatment was first received patent and distribution approval in 2015 and is the first method of pediatric care that directly combats the effects of interleukin-5 (IL-5), which regulates the function of eosinophils. In preliminary trials, a 100mg dose of the drug was shown to reduce clinically significant exacerbation of asthma by 53% versus the placebo, with overall reductions hitting 61%.
The new licence extension includes approval for use of the treatment on adult and pediatric patients in 31 European countries, covered by the European Medicines Agency.
“Asthma is the most common chronic disease in children. The availability of Nucala as the first targeted treatment available for young children with severe asthma, will help provide asthma control for these children and reassurance to their parents,” said Dr Hal Barron, Chief Scientific Officer and President, Pharmaceuticals R&D, GlaxoSmithKline.
The licence extension is positive news for the company who have seen a hike of 21% in shares since the year began, with their shares continuing to rally amidst the Sino-US tariff war only a few weeks ago.
Despite recent successes, Glaxo have shared the fate of their counterparts AstraZenica and seen a modest dip today, with shares trading at 1.583.8p, down 1.01% since trading began. Analysts from Liberum have also downgraded GlaxoSmithKline stock to a hold stance, stating that better value can be found elsewhere in the pharmaceutical market – though Glaxo is still an attractive long-term investment.
European Commission approves AstraZeneca’s Bydureon BCise device
Earlier this morning, AstraZeneca PLC (LON:AZN) announced the approval of a new easy-to-use formulation to treat patients with type-2 diabetes in Europe.
Bydureon BCise is the new formulation of once-weekly Bydureon. It is an improved single-dose, pre-filled pen device that can be used alongside other glucose-lowering drugs. Bydureon BCise will improve glycaemic control in adults with type-2 diabetes.
The approval of the European Commission follows two clinical trials that produced data to support the use of Bydureon BCise, DURATION-NEO-1 and NEO-2.
AstraZeneca is an international biopharmaceutical company operating in over 100 countries and treating millions of patients worldwide. The company drives the discovery and development of prescription medicine primarily to treat Oncology, Cardiovascular, Renal & Metabolism and Respiratory diseases.
AstraZeneca’s Vice President, Head of Cardiovascular, Renal and Metabolism, Global Medicines Development, Elisabeth Björk, has commented:
“Building on the already well-established efficacy and safety profile of once-weekly Bydureon, today’s approval of Bydureon BCise will enable us to offer an additional treatment option for patients with type-2 diabetes whose blood sugar levels are inadequately controlled by other glucose-lowering medicines together with diet and exercise.”
Whilst the European Commission has only just approved Bydureon BCise, the US Food and Drug Administration approved its use almost a year ago.
Watchdog gives green light to npower-SSE merger
The Competition and Markets Authority has given the all clear to the merger of npower and the retail arm of SSE.
Following an investigation, the competition watchdog found that the two firms did not compete closely for customers and few customers switched between the pair.
“Our analysis shows that the merger will not impact how SSE and npower set their standard variable tariff [default] prices because they are not close rivals for these customers,” Anne Lambert, chair of the CMA’s inquiry group.
The merger of the two groups is expected to be completed in the last quarter of 2018 or the first quarter of 2019.
On the results of the CME’s investigation, SSE said: “The planned transaction presents a great opportunity to create a more agile, innovative and efficient company that really delivers for customers and the energy market as a whole.”
The Labour party said that the decision by the watchdog was concerning and said the merger could lead to consumers suffering from poor service if the merger led to job cuts.
Alan Whitehead, shadow energy minister, said: “Given that both of these companies already struggle to provide good customer service, job losses in customer care as well as other departments must be avoided at all costs.”
Theresa May is to introduce a price cap on default tariffs, also known as standard variable tariffs, which will be introduced by the end of the year. This could provide issues for the energy group.
George Salmon, an equity analyst at Hargreaves Lansdown, said: “Should the cap be more severe than expected, the new business would face a fresh headwind from day one.”
The merger between SSE and npower means the big six has now shrunk to become the big five.
Shares in SSE (LON: SSE) are trading at 1.253,50 (1359GMT).
Grindr stock plans for stock market listing
The gay dating app Grindr has announced plans to go public after approved by parent company Kunlun Group.
The Chinese parent company has said that allowing the app to go public will “strengthen” its competitiveness and help business development.
In a filing to the Shenzhen stock exchange, Kunlun said: “Grindr’s listing won’t exert a huge influence on the group’s revenues and profits.”
“Meanwhile, Grindr can have an individual and direct financing platform which can support its expansion and long-term development.”
Grindr has over 27 million users globally and is a popular dating platform for lesbian, gay, bisexual and transgender people.
Based in Los Angeles, Kunlun Group bought a 61.5 percent stake in 2016 from the US founders and took full control in January in a $152 million deal.
When the app was sold, the founder Joel Simkhai said: “I’m beyond proud of what we’ve built as a team and how Grindr has been able to make a meaningful and lasting contribution to the global community.”
“We have achieved our success because of the strength and global reach of our community. I look forward to Grindr and Kunlun’s continued commitment to building tolerance, equality, and respect around the world.”
Despite the app being owned by a group based in China, the app is not the most popular gay dating app in the country. The number one position has been taken by the app Blued, which has 40 million users worldwide.
The South China Morning Post reported that the timing of the listing will depend on market conditions and regulatory approval.
Grindr was the first gay social networking app to launch on the iTunes App Store and is available in 192 countries.
WH Smith on track to be ‘in line with expectations’
WH Smith PLC said on Thursday that it expects full-year results to be in line with expectations.
The group said its travel business – focusing on mainline railway stations, airports and other travel hubs – continued to “perform strongly” whilst the high street business has come “in line with expectations”.
The retailer said: “We opened eight stores in Madrid Terminal 4 in mid-August and have also opened the first of six stores in Rio de Janeiro.”
“We now have 286 stores open internationally and we continue to see further opportunities in the international news, books and convenience travel market.”
The full results for the year to August 31 will be published on October 11 but in the meantime, WH Smith plan to focus on cost savings and margin improvements for the high street business to increase profits.
“We continue to invest in our new store format trials and have developed further our stationery ranges,” the group said in a statement.
Neil Wilson of Markets.com said: “As remarked in June, continued underinvestment in the High Street side of the business should not cloud the view that WH Smith is building a strong brand in Travel that has significant room to grow overseas.”
“This significantly reduces its exposure to the ailing UK high street – a strategy that increasingly looks like a master-stroke. While high street footfall is coming off, global air travel passenger growth is only heading up, and fast,” he added.
Shares in the group (LON: SMWH) are trading up 1.17 percent at 2.076,00 (1312GMT).
Companies leave London as Brexit fears loom
Panasonic has announced plans to migrate its European headquarters from Britain to the Netherlands in late 2018. This is following potential tax concerns related to Brexit.
The leading multinational electronics corporation is not the only company set to evacuate London following fears over the prolonged departure from the European Union.
CEO of Panasonic Europe, Laurent Abadie, has told Nikkei business daily that the company will move from just outside London to Amsterdam in October.
Laurent Abadie has revealed that Panasonic had been debating the move for the past 15 months. Primary concerns include barriers to the flow of people and goods.
The electronics giant is followed by other Japanese firms in expressing Brexit fears. MUFG, Nomura Holdings, Daiwa Securities and Sumitomo Mitsui Financial Group have also decided to move their European headquarters out of London.
The Japanese ambassador to the UK, Koji Tsuruoka, said earlier this year:
“If there is no profitability of continuing operations in the UK – not Japanese only – no private company can continue operations. So it is as simple as that.”The Japanese corporations are not alone in their fears. Earlier this year we reported that Airbus may also be forced to relocate. The major UK employer hires 14,000 people directly at 25 different sites across the country including Stevenage and Portsmouth. Instead, Airbus hinted that production may be transferred to North America, China or another European country. In June, Jeremy Hunt branded the relocation of Airbus and other firms as “completely inappropriate threats”. But Airbus and Panasonic are not alone. Earlier this year, the Independent reported that nearly 20 banks have committed to launching European Union hubs in Frankfurt since Brexit. The economy minister for Hesse has expressed confidence that Frankfurt will attract more. 60 firms are yet to decide on additional headquarters in Europe. However, of the 222 large banks, insurers, asset managers and other financial services, over a third are considering, or have confirmed, they are relocating outside the UK to the European Union. Of these banks, JP Morgan have announced up to 1,000 of their bankers working in the City of London are to move to Dublin, Frankfurt and Luxembourg. Though JP Morgan are only relocating 1,000 of their London bankers, some corporations are outright moving their headquarters from the capital. Barclays and Bank of America will move their EU headquarters from London to Dublin. Additionally, Moneygram will move its EU headquarters from London to Brussels. European Medicines Agency will relocate from London to Amsterdam, taking 890 jobs with them, and European Banking Authority from London to Paris. Whilst the foreign secretary, Boris Johnson, was reported to use an expletive when challenged about business concerns over Brexit, more and more corporations are deciding to evacuate the capital.
UKOG acquires Solo Oil’s Horse Hill stake
UK Oil & Gas plc (LON:UKOG) has acquired Solo Oil’s stake in the Horse Hill prospect located near Gatwick Airport in a bold move to increase their exposure to what has been hailed the biggest UK onshore oil find in years.
Solo Oil and UK Oil & Gas have agreed a deal for Solo’s 15% stake in Horse Hill Developments Ltd.
The deal would make UKOG a majority shareholder in Horse Hill Developments Ltd with a 71.9% stake and a 46.7% interest in the license, giving them the largest beneficial interest in the license.
The deal is to be completed by the issue of shares for a total consideration of £4.5m.
As previously reported by UK Investor Magazine, UKOG are in the process of testing the prospect for flow rates and quality of oil.
CEO Stephen Sanderson said of the acquistion:
“This further strategic acquisition firmly cements UKOG as the dominant player in the Horse Hill Portland and Kimmeridge oil discoveries and Licences. UKOG’s three recent HHDL acquisitions provide a valuable controlling interest and exemplify the rationale behind our recent change of AIM status to an operating company. With the positive Portland test results to date, UKOG, supported by its remaining three coventurers, can now steer the way towards permanent HH oil production in 2019.”
While the move may seem like Solo Oil are retreating from the prospect, the Solo Oil board have said the move is part of a wider strategic plan for the company.
Solo’s Managing Director, Dan Maling, commented:
“The Board has seized the opportunity to monetise its investment in HHDL and is pleased with the return we have made on our investment. The transaction enables a more liquid balance sheet and frees Solo from future direct operational expenditure at Horse Hill, but ensures we retain the exposure to the exciting upside potential of the projects within UKOG’s diverse portfolio. Importantly, we will retain the option to monetise our shares in UKOG at the appropriate time.”
